Web Analytics Made Easy - Statcounter

top of page

Multiple Myeloma Clinical Trials
@ Winship Cancer Institute - Emory University Atlanta, GA

Multiple Myeloma Clinical Trials @ Winship Cancer Institute - Emory University Atlanta, GA

1/37

Multiple Myeloma Clinical Trials - Currently Recruiting

NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T

2022- (R) NCT05204160

Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T

Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial

2021- (R) NCT04771078

Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial

NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM

2021 - (R) NCT04879043

Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM

NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)

2021 - (R) NCT04855136

Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)

NCT04756726: Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

2021 - (R) NCT04756726

Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

2021 - (R) NCT04722146

Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma

2020- (Active) NCT04649359

Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma

NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM

2020 - (R) NCT04570631

Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM

NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma

2020 - (R) NCT04483206

Phase 1: Personalized Autologous Transplant for Multiple Myeloma

NDMM

NCT04352205: Phase 2: Daratumumab-Based Therapy for NDMM Multiple Myeloma with Kidney failure

2020 - (R) NCT04352205

Phase 2: Daratumumab-Based Therapy for NDMM Multiple Myeloma with Kidney failure

NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

2019 - (R) NCT03989414

Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

MGUS/SMM

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

2021 - (R) NCT04754945

Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM

2019 - (R) NCT03937635

Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM

NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy

2019 - (R) NCT03820817

Phase 1: Rifaximin in Patients With Monoclonal Gammopathy

United States - Myeloma Clinical Trials | MCT Index (themyelomaclinicaltrials.com)

bottom of page